Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...
Barchart on MSN
Is Moderna Stock Underperforming the Nasdaq?
Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s ...
Stocktwits on MSN
Moderna and Super Micro top S&P 500 short interest list — are they ripe for a squeeze?
Super Micro's headwinds stemming from AI-bubble fears contrast with improving compliance, new Nvidia-powered products, and a ...
Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...
Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...
Investor's Business Daily on MSN
Stock Market Today: Indexes End Lower; Moderna Dives On FDA Memo; Synopsys, Nvidia Jump (Live Coverage)
The Dow Jones index fell on the stock market today. Synopsys popped on an investment from AI giant Nvidia. A gold stock ...
Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know. What To Know: Tuesday’s rally was driven by the release of positive ...
Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low ...
Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Friday after the company received Health Canada approval for the updated COVID-19 vaccine. What To Know: Health Canada authorized Moderna's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback